Proteomic profiling of Trastuzumab (Herceptin(R))-sensitive and -resistant SKBR-3 breast cancer cells.

Ida Pucci, Gianluca Di Cara, Patrizia Cancemi, Maria Rita Marabeti, Gianluca Di Cara, Nadia Ninfa Albanese, Maria Rita Marabeti, Rosa Musso, Gianluca Di Cara, Germana Marengo, Ida Pucci-Minafra, Patrizia Cancemi, Nadia Ninfa Albanese, Rosa Musso

Risultato della ricerca: Articlepeer review

19 Citazioni (Scopus)

Abstract

BACKGROUND:The Human Epidermal Growth Factor Receptor 2 (HER-2), overexpressed in 25-30% of breast carcinomas (BC), is the therapeutic target for trastuzumab, a recombinant humanized monoclonal antibody. The initial response to trastuzumab is often followed by drug-insensitivity within one year. Several hypotheses have been raised to explain this event, but the mechanisms behind the responses to trastuzumab are still unclear. Aim: To study the effects of short and prolonged trastuzumab treatment on the proteomic profiles of HER-2-overexpressing SKBR-3 BC cells.MATERIALS AND METHODS:Cells were treated with trastuzumab to obtain sensitive and resistant clones. The drug effects were evaluated at the phenotypical and proteomic levels.RESULTS:In the trastuzumab-resistant cells the expression of a large amount of proteins, initially affected by treatment, reverted to levels of the untreated cells.CONCLUSION:The results obtained so far illustrate for the first time a large-scale differential protein expression between trastuzumab-treated and untreated cells, and between trastuzumab-sensitive and resistant cells. We believe that the results obtained will help to increase the knowledge of the molecular effects of trastuzumab and will be useful to better-understand the drug resistance mechanisms.
Lingua originaleEnglish
pagine (da-a)489-503
Numero di pagine15
RivistaAnticancer Research
Volume33
Stato di pubblicazionePublished - 2013

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2730???
  • ???subjectarea.asjc.1300.1306???

Fingerprint

Entra nei temi di ricerca di 'Proteomic profiling of Trastuzumab (Herceptin(R))-sensitive and -resistant SKBR-3 breast cancer cells.'. Insieme formano una fingerprint unica.

Cita questo